L-Glutamine에 대한 Mechanism_Of_Action 정보 Supplemental L-glutamine's possible immunomodulatory role may be accounted for in a number of ways. L-glutamine appears to play a major role in protecting the integrity of the gastrointestinal tract and, in particular, the large intestine. During catabolic states, the integrity of the intestinal mucosa may be compromised with consequent increased intestinal permeability and translocation of Gram-negative bacteria from the large intestine into the body. The demand for L-glutamine by the intestine, as well as by cells such as lymphocytes, appears to be much greater than that supplied by skeletal muscle, the major storage tissue for L-glutamine. L-glutamine is the preferred respiratory fuel for enterocytes, colonocytes and lymphocytes. Therefore, supplying supplemental L-glutamine under these conditions may do a number of things. For one, it may reverse the catabolic state by sparing skeletal muscle L-glutamine. It also may inhibit translocation of Gram-negative bacteria from the large intestine. L-glutamine helps maintain secretory IgA, which functions primarily by preventing the attachment of bacteria to mucosal cells. L-glutamine appears to be required to support the proliferation of mitogen-stimulated lymphocytes, as well as the production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma). It is also required for the maintenance of lymphokine-activated killer cells (LAK). L-glutamine can enhance phagocytosis by neutrophils and monocytes. It can lead to an increased synthesis of glutathione in the intestine, which may also play a role in maintaining the integrity of the intestinal mucosa by ameliorating oxidative stress. The exact mechanism of the possible immunomodulatory action of supplemental L-glutamine, however, remains unclear. It is conceivable that the major effect of L-glutamine occurs at the level of the intestine. Perhaps enteral L-glutamine acts directly on intestine-associated lymphoid tissue and stimulates overall immune function by that mechanism, without passing beyond the splanchnic bed. L-isoleucine에 대한 Mechanism_Of_Action 정보 (Applies to Valine, Leucine and Isoleucine) This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. L-leucine에 대한 Mechanism_Of_Action 정보 This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. L-methionine에 대한 Mechanism_Of_Action 정보 The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine is a precursor to L-cysteine. L-cysteine itself may have antioxidant activity. L-cysteine is also a precursor to the antioxidant glutathione. Antioxidant activity of L-methionine and metabolites of L-methionine appear to account for its possible anti-hepatotoxic activity. Recent research suggests that methionine itself has free-radical scavenging activity by virtue of its sulfur, as well as its chelating ability. L-phenylalanine에 대한 Mechanism_Of_Action 정보 The mechanism of L-phenylalanine's putative antidepressant activity may be accounted for by its precursor role in the synthesis of the neurotransmitters norepinephrine and dopamine. Elevated brain norepinephrine and dopamine levels are thought to be associated with antidepressant effects. The mechanism of L-phenylalanine's possible antivitiligo activity is not well understood. It is thought that L-phenylalanine may stimulate the production of melanin in the affected skin L-threonine에 대한 Mechanism_Of_Action 정보 L-Threonine is a precursor to the amino acids glycine and serine. It acts as a lipotropic in controlling fat build-up in the liver. May help combat mental illness and may be very useful in indigestion and intestinal malfunctions. Also, threonine prevents excessive liver fat. Nutrients are more readily absorbed when threonine is present. L-valine에 대한 Mechanism_Of_Action 정보 (Applies to Valine, Leucine and Isoleucine) This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.
Pharmacology
L-Glutamine에 대한 Pharmacology 정보 Like other amino acids, glutamine is biochemically important as a constituent of proteins. Glutamine is also crucial in nitrogen metabolism. Ammonia (formed by nitrogen fixation) is assimilated into organic compounds by converting glutamic acid to glutamine. The enzyme which accomplishes this is called glutamine synthetase. Glutamine can then be used as a nitrogen donor in the biosynthesis of many compounds, including other amino acids, purines, and pyrimidines. L-isoleucine에 대한 Pharmacology 정보 They provide ingredients for the manufacturing of other essential biochemical components in the body, some of which are utilized for the production of energy, stimulants to the upper brain and helping you to be more alert. L-leucine에 대한 Pharmacology 정보 An essential amino acid. (Claim) Leucine helps with the regulation of blood-sugar levels, the growth and repair of muscle tissue (such as bones, skin and muscles), growth hormone production, wound healing as well as energy regulation. It can assist to prevent the breakdown of muscle proteins that sometimes occur after trauma or severe stress. It may also be beneficial for individuals with phenylketonuria - a condition in which the body cannot metabolize the amino acid phenylalanine L-methionine에 대한 Pharmacology 정보 L-Methionine is a principle supplier of sulfur which prevents disorders of the hair, skin and nails; helps lower cholesterol levels by increasing the liver's production of lecithin; reduces liver fat and protects the kidneys; a natural chelating agent for heavy metals; regulates the formation of ammonia and creates ammonia-free urine which reduces bladder irritation; influences hair follicles and promotes hair growth. L-methionine may protect against the toxic effects of hepatotoxins, such as acetaminophen. Methionine may have antioxidant activity. L-phenylalanine에 대한 Pharmacology 정보 Used by the brain to produce Norepinephrine, a chemical that transmits signals between nerve cells and the brain; keeps you awake and alert; reduces hunger pains; functions as an antidepressant and helps improve memory. L-threonine에 대한 Pharmacology 정보 L-Threonine is an essential amino acid that helps to maintain the proper protein balance in the body. It is important for the formation of collagen, elastin, and tooth enamel, and aids liver and lipotropic function when combined with aspartic acid and methionine. L-valine에 대한 Pharmacology 정보 L-valine is a branched-chain essential amino acid (BCAA) that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway. Valine is one of three branched-chain amino acids (the others are leucine and isoleucine) that enhance energy, increase endurance, and aid in muscle tissue recovery and repair. This group also lowers elevated blood sugar levels and increases growth hormone production. Supplemental valine should always be combined with isoleucine and leucine at a respective milligram ratio of 2:1:2. It is an essential amino acid found in proteins; important for optimal growth in infants and for growth in children and nitrogen balance in adults. The lack of L-valine may influence the growth of body, cause neuropathic obstacle, anaemia. It has wide applications in the field of pharmaceutical and food industry.
Metabolism
L-Glutamine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Glutamine Synthetase L-isoleucine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available L-methionine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Glutamine SynthetaseMethylenetetrahydrofolate reductase L-valine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Catechol O-methyltransferase (COMT)
Absorption
L-Glutamine에 대한 Absorption 정보 Absorption is efficient and occurs by an active transport mechanism L-isoleucine에 대한 Absorption 정보 Absorbed from the small intestine by a sodium-dependent active-transport process L-methionine에 대한 Absorption 정보 Absorbed from the lumen of the small intestine into the enterocytes by an active transport process. L-phenylalanine에 대한 Absorption 정보 Absorbed from the small intestine by a sodium dependent active transport process. L-valine에 대한 Absorption 정보 Absorbed from the small intestine by a sodium-dependent active-transport process.
Pharmacokinetics
L-methionine의 약물동력학자료
대사 : S-adenosylmethionine을 거쳐 homocysteine으로 전환된다. 그 후 80%가 cystathione, cysteine, taurine, inorganic sulphate로 점차로 대사된다.
L-Glutamine의 약물동력학자료
분포 : 대부분이 골격근에서 합성되고 저장된다.
Cobamamide의 약물동력학자료
흡수 :
경구 투여시 소장 원위부로부터 불규칙적으로 흡수된다.
능동 흡수에는 IF와의 복합체 형성이 필수적이며, 장관벽을 통해 수동 흡수도 가능하다.
위, 회장에 구조적 손상이나 기능적 손상이 있는 경우 흡수가 감소한다.
분포 :
위에서 위점막에 의해 분비되는 당단백인 IF (intrinsic factor)에 결합한다.
장관 점막세포 내에서 vitamin B12-IF 복합체로부터 vitamin B12가 유리된 후, 혈액 내에서 주로 특이적인 β-globulin 수송단백질인 transcobalamin II와 결합한다.
간, 골수 및 태반을 포함한 기타 조직으로 분포하며, 주로 간 (50-90%)에 저장된다.
단백결합 : 주로 transcobalamin II와 결합하며, 소량은 transcobalamin I (α-glycoprotein의 일종) 및 transcobalamin III (inter-α-glycoprotein의 일종)과 결합한다.
대사 : 장간순환
소실 :
Vitamin B12를 투여받고 있지 않는 정상인 : 많은 양이 담즙 배설 후 장간순환한다.
Vitamin B12를 투여받는 경우 : 0.1-1 mg 근육주사 또는 정맥주사 후 48시간 이내에 50-90%가 신배설된다.
Biotransformation
L-Glutamine에 대한 Biotransformation 정보 Enterocytes, Hepatic L-isoleucine에 대한 Biotransformation 정보 Hepatic L-methionine에 대한 Biotransformation 정보 Hepatic L-phenylalanine에 대한 Biotransformation 정보 Hepatic. L-phenylalanine that is not metabolized in the liver is distributed via the systemic circulation to the various tissues of the body, where it undergoes metabolic reactions similar to those that take place in the liver. L-threonine에 대한 Biotransformation 정보 Hepatic L-valine에 대한 Biotransformation 정보 Hepatic
Toxicity
L-Glutamine에 대한 Toxicity 정보 Doses of L-glutamine up to 21 grams daily appear to be well tolerated. Reported adverse reactions are mainly gastrointestinal and not common. They include constipation and bloating. There is one older report of two hypomanic patients whose manic symptoms were exacerbated following the use of 2 to 4 grams daily of L-glutamine. The symptoms resolved when the L-glutamine was stopped. These patients were not rechallenged, nor are there any other reports of this nature. L-isoleucine에 대한 Toxicity 정보 Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs L-methionine에 대한 Toxicity 정보 Doses of L-methionine of up to 250 mg daily are generally well tolerated. Higher doses may cause nausea, vomiting and headache. Healthy adults taking 8 grams of L-methionine daily for four days were found to have reduced serum folate levels and leucocytosis. Healthy adults taking 13.9 grams of L-methionine daily for five days were found to have changes in serum pH and potassium and increased urinary calcium excretion. Schizophrenic patients given 10 to 20 grams of L-methionine daily for two weeks developed functional psychoses. Single doses of 8 grams precipitated encephalopathy in patients with cirrhosis. L-phenylalanine에 대한 Toxicity 정보 L-phenylalanine will exacerbate symptoms of phenylketonuria if used by phenylketonurics. L-phenylalanine was reported to exacerbate tardive dyskinesia when used by some with schizophrenia. L-valine에 대한 Toxicity 정보 Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs.
Drug Interactions
L-Glutamine에 대한 Drug_Interactions 정보 Not Available L-isoleucine에 대한 Drug_Interactions 정보 Not Available L-methionine에 대한 Drug_Interactions 정보 Not Available L-phenylalanine에 대한 Drug_Interactions 정보 Not Available L-valine에 대한 Drug_Interactions 정보 Not Available
L-Glutamine에 대한 Description 정보 A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells. [PubChem] L-isoleucine에 대한 Description 정보 An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of leucine. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels. [PubChem] L-leucine에 대한 Description 정보 An essential branched-chain amino acid important for hemoglobin formation. [PubChem] L-methionine에 대한 Description 정보 A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. [PubChem] L-phenylalanine에 대한 Description 정보 An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem] L-threonine에 대한 Description 정보 An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins. [PubChem] L-valine에 대한 Description 정보 A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway. [PubChem]
Dosage Form
L-Glutamine에 대한 Dosage_Form 정보 Not Available L-isoleucine에 대한 Dosage_Form 정보 Capsule OralPowder OralTablet Oral L-leucine에 대한 Dosage_Form 정보 Capsule OralPowder OralTablet Oral L-methionine에 대한 Dosage_Form 정보 Capsule OralPowder OralTablet OralTablet Oral
Drug Category
L-isoleucine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-leucine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-methionine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-phenylalanine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-threonine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-valine에 대한 Drug_Category 정보 Dietary supplementsEssential Amino AcidsMicronutrients
Smiles String Canonical
L-Glutamine에 대한 Smiles_String_canonical 정보 NC(CCC(N)=O)C(O)=O L-isoleucine에 대한 Smiles_String_canonical 정보 CCC(C)C(N)C(O)=O L-leucine에 대한 Smiles_String_canonical 정보 CC(C)CC(N)C(O)=O L-methionine에 대한 Smiles_String_canonical 정보 CSCCC(N)C(O)=O L-phenylalanine에 대한 Smiles_String_canonical 정보 NC(CC1=CC=CC=C1)C(O)=O L-threonine에 대한 Smiles_String_canonical 정보 CC(O)C(N)C(O)=O L-valine에 대한 Smiles_String_canonical 정보 CC(C)C(N)C(O)=O
Smiles String Isomeric
L-Glutamine에 대한 Smiles_String_isomeric 정보 N[C@@H](CCC(N)=O)C(O)=O L-isoleucine에 대한 Smiles_String_isomeric 정보 CC[C@H](C)[C@H](N)C(O)=O L-leucine에 대한 Smiles_String_isomeric 정보 CC(C)C[C@@H](N)C(O)=O L-methionine에 대한 Smiles_String_isomeric 정보 CSCC[C@H](N)C(O)=O L-phenylalanine에 대한 Smiles_String_isomeric 정보 N[C@@H](CC1=CC=CC=C1)C(O)=O L-threonine에 대한 Smiles_String_isomeric 정보 C[C@@H](O)[C@H](N)C(O)=O L-valine에 대한 Smiles_String_isomeric 정보 CC(C)[C@H](N)C(O)=O
InChI Identifier
L-Glutamine에 대한 InChI_Identifier 정보 InChI=1/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1/f/h9H,7H2 L-isoleucine에 대한 InChI_Identifier 정보 InChI=1/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1/f/h8H L-leucine에 대한 InChI_Identifier 정보 InChI=1/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/f/h8H L-methionine에 대한 InChI_Identifier 정보 InChI=1/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1/f/h7H L-phenylalanine에 대한 InChI_Identifier 정보 InChI=1/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1/f/h11H L-threonine에 대한 InChI_Identifier 정보 InChI=1/C4H9NO3/c1-2(6)3(5)4(7)8/h2-3,6H,5H2,1H3,(H,7,8)/t2-,3+/m1/s1/f/h7H L-valine에 대한 InChI_Identifier 정보 InChI=1/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1/f/h7H
Chemical IUPAC Name
L-Glutamine에 대한 Chemical_IUPAC_Name 정보 (2S)-2,5-diamino-5-oxopentanoic acid L-isoleucine에 대한 Chemical_IUPAC_Name 정보 (2S,3S)-2-amino-3-methylpentanoic acid L-leucine에 대한 Chemical_IUPAC_Name 정보 2-amino-4-methylpentanoic acid L-methionine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-4-methylsulfanylbutanoic acid L-phenylalanine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-3-phenylpropanoic acid L-threonine에 대한 Chemical_IUPAC_Name 정보 (2S,3R)-2-amino-3-hydroxybutanoic acid L-valine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-3-methylbutanoic acid
Drug-Induced Toxicity Related Proteins
GLUTAMINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Latent transforming growth factor beta-binding protein, isoform 1L Drug:glutamine Toxicity:apoptosis. [바로가기]Replated Protein:Glucosamine--fructose-6-phosphate aminotransferase Drug:glutamine Toxicity:arrest cellular proliferation . [바로가기]Replated Protein:Epidermal growth factor receptor Drug:glutamine Toxicity:arrest cellular proliferation . [바로가기]Replated Protein:Glucosamine--fructose-6-phosphate aminotransferase Drug:glutamine Toxicity:apoptosis. [바로가기]LYSINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Tamm-Horsfall protein Drug:Lysine Toxicity:persisting acute renal failure . [바로가기]METHIONINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:NMDA receptor-regulated protein Drug:methionine Toxicity:cerebrovascular disease. [바로가기]Replated Protein:Cystathionine beta-synthase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [바로가기]Replated Protein:Methylenetetrahydrofolate reductase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [바로가기]
사용자컨텐츠
항목
내용
최근정보수정일 2025-10-29
본 수정일 정보는 허가정보 이외의 기타정보 수정일을 의미하므로, 허가정보수정일은 본문에 표기된 날짜를 참조하시기 바랍니다.
알림
상세정보는 식품의약품안전처의 제품허가사항을 토대로 작성되었으며 요약정보는 상세정보 및 기타문헌을 기반으로 드럭인포에서 편집한 내용입니다. 제품허가사항의 목차와 다소 상이할 수 있습니다.
경고
드럭인포 의약학술정보는 식품의약품안전처의 제품허가사항, 학술문헌, 제약회사 제공정보 등을 근거로 작성된 참고 정보입니다.
정보의 정확성을 위해 노력하고 있으나 편집상의 오류, 허가사항 변경, 추가적인 학술연구 또는 임상연구 발표 등으로 인해 발생하는 문제에 대해 드럭인포는
책임을 지지 않습니다. 자세한 내용은 “책임의 한계 및 법적고지”를 참조해 주십시오.
반드시 제조·수입사, 판매사, 의사, 약사에게 최종적으로 확인하시기 바랍니다.
전화: 02-3486-1061 ㅣ 이메일: webmaster@druginfo.co.kr
전문/일반
